Regeneron gains 9% as it raises 2012 Eylea forecast to $500-$550
This article was originally published in Scrip
Executive Summary
Regeneron has had another stellar quarter, as its eye drug Eylea (aflibercept; also known as VEGF Trap-Eye) outperformed by a wide margin – coming in with $124 million in net US product sales for 1Q12 in wet age-related macular degeneration, and beating consensus.